DK2970257T3 - Apoptoseinducerende midler til behandling af cancer og immun- og autoimmunsygdomme - Google Patents

Apoptoseinducerende midler til behandling af cancer og immun- og autoimmunsygdomme Download PDF

Info

Publication number
DK2970257T3
DK2970257T3 DK14709488.2T DK14709488T DK2970257T3 DK 2970257 T3 DK2970257 T3 DK 2970257T3 DK 14709488 T DK14709488 T DK 14709488T DK 2970257 T3 DK2970257 T3 DK 2970257T3
Authority
DK
Denmark
Prior art keywords
methyl
amino
yloxy
pyrrolo
dimethylcyclohex
Prior art date
Application number
DK14709488.2T
Other languages
English (en)
Inventor
Zhi-Fu Tao
Xilu Wang
Michael D Wendt
Andrew J Souers
Andrew S Judd
Aaron Kunzer
Gerard Sullivan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51529947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2970257(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK2970257T3 publication Critical patent/DK2970257T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (11)

1. Forbindelse valgt fra gruppen, der består af: 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)- N-[(4-{[(2R)-l,4-dioxan-2-ylmethyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(3-nitro-4-{ [(5R,8R)-1-oxaspiro[4.5]dec-8-ylmethyl] amino }phenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)- N-[(4-{[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)- N-({4-[(l,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2- (lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)- N-[(4-{[(2S)-l,4-dioxan-2-ylmethyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{ [4-({ [4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl}amino)-3-nitrophenyl] sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{ ^-(d-chlorphenylj-d^-dimethylcyclohex-l-en-l-y^methylJpiperazin-l-ylj-N-ECd-} [(3-hydroxyoxetan-3-yl)methyl] amino }-3-nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{ [2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)- N-{[4-({ [(2S,5R)-5-methyl-l,4-dioxan-2-yl]methyl}amino)-3- nitrophenyl] sulfonyl}-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)- N-[(4-{[(4-cyanotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid; 4-(4-{[2-(4-chlor-2-fluorphenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamid; og 4- [4- ({2- [4-(difluormethyl)pheny)] -4,4-dimethylcyctohex-1 -en-1 - yl)methyl)piperazin-1 -yl] -N- ({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)-2-(lH-pyrrolo[2,3-b]pyridin-5- yloxy)benzamid; og terapeutisk acceptable salte deraf.
2. Forbindelse ifølge krav 1, hvor forbindelsen er 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl] methyl }piperazin-l-yl)-N-{ [4-({ [(2S,5R)-5-methyl- 1,4-dioxan-2-yl]methyl} amino)-3-nitrophenyl] sulfonyl )-2-(1 H-pyrrolo [2,3-b]pyridin-5-yloxy)benzamid eller et terapeutisk acceptabelt salt deraf.
3. Forbindelse ifølge krav 2, der omfatter et enantiomert overskud af 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl] methyl)piperazin-1 -yl)-N- {[4- ({[(2S,5R)-5-methyl- l,4-dioxan-2-yl]methyl}amino)-3-nitrophenyl] sulfonyl }-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid eller det terapeutisk acceptable salt deraf ved ca. 95 % til ca. 99 %.
4. Forbindelse ifølge krav 2, der omfatter et enantiomert overskud af 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{ [4- ({[(2S,5R)-5-methyl- l,4-dioxan-2-yl]methyl}amino)-3-nitrophenyl] sulfonyl }-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid eller det terapeutisk acceptable salt deraf ved mere end ca. 99 %.
5. Forbindelse ifølge krav 2, der omfatter en absolut stereoisomer af 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{ [4- ({[(2S,5R)-5-methyl- l,4-dioxan-2-yl]methyl}amino)-3-nitrophenyl] sulfonyl }-2-(lH-pyrrolo[2,3-b]pyridin-5-yloxy)benzamid eller det terapeutisk acceptable salt deraf.
6. Forbindelse ifølge krav 1 eller et terapeutisk acceptabelt salt deraf til anvendelse i en fremgangsmåde til behandling af blærecancer, hjernecancer, brystcancer, knoglemarvscancer, cervixcancer, kronisk lymfocytisk leukæmi, kolorektal cancer, øsofaguscancer, hepatocellulær cancer, lymfoblastisk leukæmi, follikulært lymfom, lymfoide maligniteter af T-celle- eller B-celle-oprindelse, melanom, myeloid leukæmi, myelom, oral cancer, ovariecancer, ikke-småcellet lungecancer, kronisk lymfoid leukæmi, myelom, prostatacancer, småcellet lungecancer eller miltcancer hos et indvid, der har brug for behandling, hvilken fremgangsmåde omfatter administrering til individet af en terapeutisk effektiv mængde af en forbindelse ifølge krav 1 eller et terapeutisk acceptabelt salt deraf.
7. Forbindelse til anvendelse ifølge krav 6, hvor fremgangsmåden omfatter administrering til individet af en sammensætning, der omfatter et excipiens og en terapeutisk effektiv mængde af en forbindelse ifølge krav 1 eller et terapeutisk acceptabelt salt deraf.
8. Forbindelse til anvendelse ifølge krav 6, hvor fremgangsmåden omfatter administrering til individet af en terapeutisk effektiv mængde af forbindelsen ifølge krav 1 eller et terapeutisk acceptabelt salt deraf og en terapeutisk effektiv mængde af ét yderligere terapeutisk middel eller mere end ét yderligere terapeutisk middel.
9. Forbindelse ifølge krav 1 eller et terapeutisk acceptabelt salt deraf til anvendelse i en fremgangsmåde til behanlding af systemisk lupus erythematosus, lupus nephritis eller Sjogrens syndrom hos et individ, der har brug for behandling, hvor fremgangsmåden omfatter administrering til individet af en terapeutisk effektiv mængde af forbindelsen ifølge krav 1 eller et terapeutisk acceptabelt salt deraf.
10. Forbindelse til anvendelse ifølge krav 9, hvor fremgangsmåden omfatter administrering til individet af en sammensætning, der omfatter et excipiens og en terapeutisk effektiv mængde af forbindelsen ifølge krav 1 eller et terapeutisk acceptabelt salt deraf.
11. Forbindelse til anvendelse ifølge krav 9, hvor fremgangsmåden omfatter administrering til individet af en terapeutisk effektiv mængde af forbindelsen ifølge krav 1 eller et terapeutisk acceptabelt salt deraf og en terapeutisk effektiv mængde af ét yderligere terapeutisk middel eller mere end ét yderligere terapeutisk middel.
DK14709488.2T 2013-03-14 2014-02-21 Apoptoseinducerende midler til behandling af cancer og immun- og autoimmunsygdomme DK2970257T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781070P 2013-03-14 2013-03-14
US14/176,506 US20140275082A1 (en) 2013-03-14 2014-02-10 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PCT/US2014/017751 WO2014158528A1 (en) 2013-03-14 2014-02-21 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Publications (1)

Publication Number Publication Date
DK2970257T3 true DK2970257T3 (da) 2018-09-10

Family

ID=51529947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14709488.2T DK2970257T3 (da) 2013-03-14 2014-02-21 Apoptoseinducerende midler til behandling af cancer og immun- og autoimmunsygdomme

Country Status (36)

Country Link
US (6) US20140275082A1 (da)
EP (2) EP2970257B1 (da)
JP (4) JP6449222B2 (da)
KR (2) KR102260645B1 (da)
CN (2) CN107987075B (da)
AR (2) AR095263A1 (da)
AU (2) AU2014242104B2 (da)
BR (1) BR112015021115B1 (da)
CA (2) CA3110552A1 (da)
CL (2) CL2015002640A1 (da)
CR (1) CR20150510A (da)
CY (1) CY1120862T1 (da)
DK (1) DK2970257T3 (da)
DO (1) DOP2018000026A (da)
ES (1) ES2689679T3 (da)
GT (1) GT201500248A (da)
HK (1) HK1220189A1 (da)
HR (1) HRP20181403T8 (da)
HU (1) HUE038983T2 (da)
IL (3) IL240010B (da)
LT (1) LT2970257T (da)
MX (1) MX360541B (da)
MY (1) MY178821A (da)
NZ (1) NZ631701A (da)
PE (2) PE20191555A1 (da)
PL (1) PL2970257T4 (da)
PT (1) PT2970257T (da)
RS (1) RS57750B1 (da)
RU (2) RU2662812C2 (da)
SG (2) SG10201908388UA (da)
SI (1) SI2970257T1 (da)
TW (2) TWI717662B (da)
UA (1) UA120035C2 (da)
UY (1) UY35406A (da)
WO (1) WO2014158528A1 (da)
ZA (1) ZA201505203B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
JP2015502366A (ja) 2011-12-13 2015-01-22 バック インスティテュート フォー リサーチ オン エイジング 薬物療法を改善するための方法
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
AP2017009733A0 (en) 2014-09-12 2017-02-28 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN104370905B (zh) * 2014-10-22 2016-06-01 南京友杰医药科技有限公司 Bcl-2抑制剂ABT-199的合成
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
JP6663438B2 (ja) 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
AU2016362777B2 (en) 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CO2018009205A2 (es) * 2016-02-27 2018-09-20 Hpvvax Llc Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109641897B (zh) * 2016-09-01 2021-12-07 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
CN108658983B (zh) * 2017-06-26 2019-12-20 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
AU2019207611A1 (en) 2018-01-10 2020-07-09 Recurium Ip Holdings, Llc Benzamide compounds
BR112020022092A2 (pt) 2018-04-29 2021-02-02 Beigene, Ltd. compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica
CN110577525A (zh) * 2018-06-11 2019-12-17 北京万全德众医药生物技术有限公司 一种维奈妥拉中间体的制备方法
CN116199686A (zh) * 2018-10-29 2023-06-02 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物
CN113825754B (zh) 2019-05-24 2023-09-22 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
US20230301989A1 (en) * 2020-08-21 2023-09-28 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
EP4298098A1 (en) * 2021-02-01 2024-01-03 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
CN113046433B (zh) * 2021-03-19 2022-12-02 武汉大学 细胞因子il1f9在制备检测、预防和治疗肿瘤的产品中的应用
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
JPH11512429A (ja) 1995-09-15 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー アミノアリールオキサゾリジノン ｎ−オキシド
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
RU2001103044A (ru) 1998-07-06 2003-08-10 Бристол-Маерс Сквибб Ко. (Us) Бенилсульфонамиды в качестве двойных антагонистов ангиотензиновых эндотелиновых рецепторов
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2001047891A1 (fr) 1999-12-28 2001-07-05 Eisai Co., Ltd. Composes heterocylciques contenant des groupes de sulfamide
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
SK14642003A3 (sk) 2001-06-06 2004-12-01 Eli Lilly And Company Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
PT1480679E (pt) 2002-02-26 2007-07-18 Astrazeneca Ab Fórmulação farmacêutica de iressa compreendendo um derivado de celulose solúvel em água
ES2342660T3 (es) 2002-02-26 2010-07-12 Astrazeneca Ab Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
WO2006026501A1 (en) 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
FR2884821B1 (fr) * 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
BRPI0610828A2 (pt) 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
AU2006261993B2 (en) 2005-06-22 2011-11-17 Plexxikon, Inc. Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
EP2061560A2 (en) 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
EP2148867B1 (en) 2007-04-19 2014-09-10 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
EP2195027A4 (en) 2007-10-01 2011-11-16 Univ Johns Hopkins METHOD FOR THE TREATMENT OF NEUROLOGICAL AUTOIMMUNE DISEASES WITH CYCLOPHOSPHAMID
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
NZ585085A (en) 2007-11-16 2012-08-31 Abbott Lab Method of treating arthritis using arylsulfonamide compounds
CA2708223A1 (en) 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
JP5635912B2 (ja) 2008-01-15 2014-12-03 アッヴィ・インコーポレイテッド 改善された哺乳動物発現ベクター及びその使用
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ME02642B (me) 2008-12-05 2017-06-20 Abbvie Inc Sulfonamid derivati i kao BCL- 2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
GB2466622A (en) * 2008-12-23 2010-06-30 Trinity College Dublin Alpha2-Adrenoceptor Ligands
ES2536090T3 (es) 2009-01-19 2015-05-20 Abbvie Inc. Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias
BRPI1006115A8 (pt) 2009-01-19 2017-09-26 Abbott Lab "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PL2435432T6 (pl) 2009-05-26 2024-02-12 Abbvie Ireland Unlimited Company Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
RU2598345C2 (ru) * 2010-10-29 2016-09-20 Эббви Инк. Твердые дисперсии, содержащие средства, вызывающие апоптоз
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
US10081628B2 (en) 2018-09-25
TWI717662B (zh) 2021-02-01
BR112015021115B1 (pt) 2022-05-03
SI2970257T1 (sl) 2018-10-30
AU2018226476B2 (en) 2019-10-10
RU2662812C2 (ru) 2018-07-31
PE20191555A1 (es) 2019-10-24
PL2970257T4 (pl) 2019-01-31
CN105026394A (zh) 2015-11-04
JP2021167330A (ja) 2021-10-21
KR102260645B1 (ko) 2021-06-08
CA3110552A1 (en) 2014-10-02
PL2970257T3 (pl) 2018-11-30
PT2970257T (pt) 2018-10-25
HRP20181403T1 (hr) 2018-11-30
SG11201507363UA (en) 2015-10-29
RS57750B1 (sr) 2018-12-31
NZ631701A (en) 2017-05-26
TW201524976A (zh) 2015-07-01
DOP2018000026A (es) 2018-10-31
JP2016517406A (ja) 2016-06-16
US20210403467A1 (en) 2021-12-30
AU2014242104B2 (en) 2018-07-05
CL2018000353A1 (es) 2018-07-13
RU2018127315A (ru) 2019-03-13
HK1220189A1 (zh) 2017-04-28
CN107987075B (zh) 2020-12-01
US20170008891A1 (en) 2017-01-12
MX360541B (es) 2018-10-19
LT2970257T (lt) 2018-09-25
CR20150510A (es) 2015-12-11
BR112015021115A2 (pt) 2017-10-10
MY178821A (en) 2020-10-20
JP2020180145A (ja) 2020-11-05
CY1120862T1 (el) 2019-12-11
AR095263A1 (es) 2015-09-30
AU2014242104A1 (en) 2015-07-30
MX2015011641A (es) 2015-12-16
GT201500248A (es) 2017-09-14
HRP20181403T8 (hr) 2018-12-28
IL287315A (en) 2021-12-01
UA120035C2 (uk) 2019-09-25
JP2019038820A (ja) 2019-03-14
AU2018226476A1 (en) 2018-09-27
HUE038983T2 (hu) 2018-12-28
AR117768A2 (es) 2021-08-25
KR20150130486A (ko) 2015-11-23
WO2014158528A1 (en) 2014-10-02
US20150299197A1 (en) 2015-10-22
RU2015143917A (ru) 2017-04-18
CN107987075A (zh) 2018-05-04
SG10201908388UA (en) 2019-10-30
US20200331907A1 (en) 2020-10-22
EP2970257A1 (en) 2016-01-20
AU2018226476C1 (en) 2020-01-16
TW201908316A (zh) 2019-03-01
ES2689679T3 (es) 2018-11-15
JP6449222B2 (ja) 2019-01-09
US20140275082A1 (en) 2014-09-18
CA2899041A1 (en) 2014-10-02
IL265296A (en) 2019-05-30
IL240010B (en) 2019-09-26
PE20151555A1 (es) 2015-12-06
RU2018127315A3 (da) 2021-10-05
KR20210021613A (ko) 2021-02-26
CN105026394B (zh) 2017-12-29
TWI675835B (zh) 2019-11-01
UY35406A (es) 2014-09-30
IL240010A0 (en) 2015-09-24
EP2970257B1 (en) 2018-05-30
CL2015002640A1 (es) 2016-03-18
ZA201505203B (en) 2016-07-27
EP3415514A1 (en) 2018-12-19
US20180354952A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
AU2018226476B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2567857C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА, ИНГИБИРУЮЩИЕ АКТИВНОСТЬ АНТИАПОПТИЧЕСКИХ БЕЛКОВ Bcl-2
CN104136435B (zh) 溴结构域抑制剂
TWI537269B (zh) 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑
CA2799280A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases